$CNXC

Concentrix Corp reported Q2 2026 revenue of $2.45B, down 1.2% YoY, and a net loss of $988.11M, versus prior-year income of $88.11M. Growth in banking and retail was offset by declines in tech and healthcare. The company is focusing on cost reduction and AI-driven services.

Concentrix (CNXC) trades at a low P/E of 2.68 despite strong operational metrics, including adjusted EPS of $2.92 and adjusted free cash flow guidance of $630M-$650M. Revenue declined 0.5% YoY, with Q4 guidance of a 3%-5% drop. Management highlights growth in newer, higher-margin services, but debt and top-line contraction raise concerns. Hedge fund ownership fell to 21, and short interest is high at 16.55%.

Concentrix (CNXC) reported a net loss in Q3 and issued weak guidance, expecting a revenue decline and operating loss for the year. Its share price fell 7.77% in one day and 22.54% over a month, with a 39.55% decline year-to-date. Analysts estimate a fair value of $35.25, suggesting a 29% undervaluation, but risks include integration challenges and a $4.9 billion debt load.

Concentrix (CNXC), Huron (HURN), and TaskUs (TASK) shares surged 10.8%, 7.3%, and 6.3% respectively after Accenture's strong earnings and outlook boosted IT consulting peers. IBM also announced a self-hosted AI option. Concentrix reported a Q3 net loss of $988.1M, but non-GAAP earnings of $2.92 per share and record adjusted free cash flow of $218.3M.

Synopsys (SNPS) shares rose 10.8% to $482.23 after issuing FY27 guidance above estimates. Accenture (ACN) gained 18.3% to $216.66 on better-than-expected Q4 results and FY27 sales guidance. Vicor (VICR) rose 11.4% to $321.99 after raising Q3 revenue growth guidance. Other stocks also saw significant gains.

BofA Securities lowered its price target for Concentrix Corp. (NASDAQ: CNXC) to $29.00 from $30.00, citing macroeconomic headwinds. The company's Q3 profitability exceeded guidance but revenue missed estimates. Management highlighted growth in newer, higher-margin revenue streams and raised the dividend to $0.37 per share. CNXC stock has fallen 15% in the past week and 38% year-to-date, despite analysts seeing potential undervaluation and a return to profitability.

Concentrix Corp (CNXC) reported Q3 earnings with a $0.21 EPS beat ($2.92) but a $30M revenue miss ($2.45B vs. $2.48B est). Shares initially dropped 9.77% before recovering 3.12%. Management highlighted AI-driven revenue growth (50% of total) and cash flow strength ($218M), but revenue declines due to specific client exits and offshoring. The dividend was raised to $0.37/share. Growth is expected to return in 2028, with key catalysts including Q4 earnings and debt paydown milestones.

Concentrix (CNXC) reported fiscal Q3 revenue below estimates due to client shifts, but earnings beat expectations. CEO Christopher Caldwell attributed the shortfall to client preferences, not customer loss. The stock initially dropped but recovered, up 3% by midday. Analysts' average price target is $33.50, over 30% above current levels.

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

Concentrix (CNXC) declared a $0.37 per share quarterly dividend, maintaining the previous rate. The forward yield is 5.95%. The dividend is payable on November 3 to shareholders of record on October 23. The company also expects new business revenues to exceed $6 billion in 2027 and targets 2.2x net leverage. CNXC reported Q3 2026 Non-GAAP EPS of $2.92, beating estimates by $0.22, but revenue of $2.45B missed by $30M.